Skip to main content
SpringerLink
Log in

Toxoplasma gondii in Solid Organ and Stem Cell Transplant: Prevention and Treatment

  • Reference work entry
  • First Online:
Emerging Transplant Infections

  • 1193 Accesses

Abstract

Transplant recipients are a population at high risk for various opportunistic infections, including toxoplasmosis. Toxoplasma infection is particularly life-threatening in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients, primarily occurring through reactivation of latent infection or primary infection, respectively. Epidemiological, clinical features and levels of risk vary according to the transplanted organ, the pretransplant serologic status of both donor and recipient, and the time after engraftment. The diagnosis is guided by clinical symptoms and signs (although frequently nonspecific), imaging, and other diagnostic findings. Molecular methods, i.e., real-time PCRs, are the mainstay of Toxoplasma detection and should be performed for diagnosis in the blood or any other pertinent site. Despite the lack of transplant-specific therapeutic guidelines, the combination of pyrimethamine-sulfadiazine has been proposed as the first-line curative treatment, based on clinical trials in HIV-infected population. Prevention of toxoplasmosis includes patient education about hygienic rules to prevent primary infection, but also serologic screening of donors and recipients, chemoprophylaxis, and follow-up of patients after transplantation. Although there are not well-standardized protocols adapted to the type of graft, patient management is extensively discussed in this chapter, which provides an overview of the usual diagnostic, therapeutic, and preventive strategies aimed at improving the clinical management of transplant recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 2013;91(7):501–8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Robert-Gangneux F, Dardé M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Robert-Gangneux F, Sterkers Y, Yera H, Accoceberry I, Menotti J, Cassaing S, et al. Molecular diagnosis of toxoplasmosis in Immunocompromised patients: a 3-year Multicenter retrospective study. J Clin Microbiol. 2015;53(5):1677–84.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS. France Emerg Infect Dis. 2014;20(9):1490–7.

    Article  PubMed  Google Scholar 

  5. Derouin F, Pelloux H. ESCMID study group on clinical parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14(12):1089–101.

    Article  CAS  PubMed  Google Scholar 

  6. Fernàndez-Sabé N, Cervera C, Fariñas MC, Bodro M, Muñoz P, Gurguí M, et al. Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis. 2012;54(3):355–61.

    Article  PubMed  Google Scholar 

  7. Desoubeaux G, Cabanne É, Franck-Martel C, Gombert M, Gyan E, Lissandre S, et al. Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: a single-centre prospective study assessing PCR-based diagnosis. J Clin Pathol. 2016;69(8): 726–30.

    Article  CAS  PubMed  Google Scholar 

  8. Sumi M, Aosai F, Norose K, Takeda W, Kirihara T, Sato K, et al. Acute exacerbation of Toxoplasma gondii infection after hematopoietic stem cell transplantation: five case reports among 279 recipients. Int J Hematol. 2013;98(2):214–22.

    Article  PubMed  Google Scholar 

  9. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, et al. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis. 2005;40(1):67–78.

    Article  PubMed  Google Scholar 

  10. Meers S, Lagrou K, Theunissen K, Dierickx D, Delforge M, Devos T, et al. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis. 2010;50(8):1127–34.

    Article  PubMed  Google Scholar 

  11. Robert-Gangneux F, Meroni V, Dupont D, Botterel F, Garcia JMA, Brenier-Pinchart M-P, et al. Toxoplasmosis in transplant recipients, Europe, 2010–2014. Emerg Infect Dis. 2018;24(8):1497–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Štajner T, Vasiljević Z, Vujić D, Marković M, Ristić G, Mićić D, et al. Atypical strain of Toxoplasma gondii causing fatal reactivation after hematopoietic stem cell Transplantion in a patient with an underlying immunological deficiency. J Clin Microbiol. 2013;51(8):2686–90.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Vaughan LB, Wenzel RP. Disseminated toxoplasmosis presenting as septic shock five weeks after renal transplantation. Transpl Infect Dis. 2013;15(1):E20–4.

    Article  CAS  PubMed  Google Scholar 

  14. Baliu C, Sanclemente G, Cardona M, Castel MA, Perez-Villa F, Moreno A, et al. Toxoplasmic encephalitis associated with meningitis in a heart transplant recipient. Transpl Infect Dis. 2014;16(4):631–3.

    Article  CAS  PubMed  Google Scholar 

  15. Gajurel K, Dhakal R, Montoya JG. Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations. Curr Opin Infect Dis. 2015;28(4):283–92.

    Article  CAS  PubMed  Google Scholar 

  16. Robert-Gangneux F, Djurković-Djaković O. Serological and molecular screening of umbilical cord blood for toxoplasma gondii infection; a reply to Botein et al. Transpl Infect Dis. 2019;21(4):e13127.

    Article  PubMed  Google Scholar 

  17. Schmidt M, Sonneville R, Schnell D, Bigé N, Hamidfar R, Mongardon N, et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a Multicenter study. Clin Infect Dis. 2013;57(11):1535–41.

    Article  PubMed  Google Scholar 

  18. Conrad A, Le Maréchal M, Dupont D, Ducastelle-Leprêtre S, Balsat M, Labussière-Wallet H, et al. A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication. Clin Microbiol Infect. 2016;22(7):636–41.

    Google Scholar 

  19. Khalaf AM, Hashim MA, Alsharabati M, Fallon K, Cure JK, Pappas P, et al. Late-onset cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantation. Am J Case Rep. 2017;18:246–50.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Robin C, Leclerc M, Angebault C, Redjoul R, Beckerich F, Cabanne L, et al. Toxoplasmosis as an early complication of allogeneic hematopoietic cell transplantation. J Am Soc Blood Marrow Transplant. 2019;S1083-8791(19)30507-5.

    Google Scholar 

  21. Dard C, Marty P, Brenier-Pinchart M-P, Garnaud C, Fricker-Hidalgo H, Pelloux H, et al. Management of toxoplasmosis in transplant recipients: an update. Expert Rev Anti-Infect Ther. 2018;16(6):447–60.

    Article  CAS  PubMed  Google Scholar 

  22. Luft BJ, Naot Y, Araujo FG, Stinson EB, Remington JS. Primary and reactivated toxoplasma infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med. 1983;99(1):27–31.

    Article  CAS  PubMed  Google Scholar 

  23. Wreghitt TG, Gray JJ, Pavel P, Balfour A, Fabbri A, Sharpies LD, et al. Efficacy of pyrimethamine for the prevention of donor-acquired toxoplasma gondii infection in heart and heart-lung transplant patients. Transpl Int. 1992;5(4):197–200.

    Article  CAS  PubMed  Google Scholar 

  24. Dhakal R, Gajurel K, Montoya JG. Toxoplasmosis in the non-orthotopic heart transplant recipient population, how common is it? Any indication for prophylaxis? Curr Opin Organ Transplant. 2018;23(4):407–16.

    Article  PubMed  Google Scholar 

  25. Autier B, Dion S, Robert-Gangneux F. The liver as an organ at risk for toxoplasma transmission during transplantation: myth or reality? J Clin Pathol. 2018;71(9):763–6.

    Article  CAS  PubMed  Google Scholar 

  26. Barge-Caballero E, Almenar-Bonet L, Crespo-Leiro MG, Brossa-Loidi V, Rangel-Sousa D, Gómez-Bueno M, et al. Preoperative toxoplasma gondii serostatus does not affect long-term survival of cardiac transplant recipients. Analysis of the Spanish heart transplantation registry. Int J Cardiol. 2018;250:183–7.

    Article  PubMed  Google Scholar 

  27. Segall L, Moal M-C, Doucet L, Kergoat N, Bourbigot B. Toxoplasmosis-associated hemophagocytic syndrome in renal transplantation. Transpl Int. 2006;19(1):78–80.

    Article  PubMed  Google Scholar 

  28. Gatti-Mays ME, Manion M, Bowen LN, Brown GT, Danner RL, Khan O, et al. Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report. Bone Marrow Transplant. 2016;51(12):1622–4.

    Article  CAS  PubMed  Google Scholar 

  29. Blanche P, Robert F, Dupouy-Camet J, Sicard D. Toxoplasmosis-associated hemophagocytic syndrome in a patient with AIDS: diagnosis by the polymerase chain reaction. Clin Infect Dis. 1994;19(5):989–90.

    Article  CAS  PubMed  Google Scholar 

  30. van Bilsen WPH, van den Berg CHSB, Rijnders BJA, Brinkman K, Mulder JW, Gelinck LBS, et al. Immune reconstitution inflammatory syndrome associated with toxoplasmic encephalitis in HIV-infected patients. AIDS. 2017;31(10):1415–24.

    Google Scholar 

  31. Duband S, Cornillon J, Tavernier E, Dumollard J-M, Guyotat D, Péoc’h M. Toxoplasmosis with hemophagocytic syndrome after bone marrow transplantation: diagnosis at autopsy. Transpl Infect Dis. 2008;10(5):372–4.

    Article  CAS  PubMed  Google Scholar 

  32. Gay J, Gendron N, Verney C, Joste V, Dardé M-L, Loheac C, et al. Disseminated toxoplasmosis associated with hemophagocytic syndrome after kidney transplantation: a case report and review. Transpl Infect Dis. 2019;21:e13154.

    Article  PubMed  Google Scholar 

  33. Douet T, Armengol C, Charpentier E, Chauvin P, Cassaing S, Iriart X, et al. Performance of seven commercial automated assays for the detection of low levels of anti-Toxoplasma IgG in French immunocompromised patients. Parasite. 2019;26:51.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Fricker-Hidalgo H, Bulabois C-E, Brenier-Pinchart M-P, Hamidfar R, Garban F, Brion J-P, et al. Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin Infect Dis. 2009;48(2):e9–15.

    Article  PubMed  Google Scholar 

  35. Kaiser K, Van Loon AM, Pelloux H, Ferrandiz J, Picot S, Wallace P, et al. Multicenter proficiency study for detection of Toxoplasma gondii in amniotic fluid by nucleic acid amplification methods. Clin Chim Acta. 2007;375(1):99–103.

    Google Scholar 

  36. Sterkers Y, Varlet-Marie E, Cassaing S, Brenier-Pinchart M-P, Brun S, Dalle F, et al. Multicentric comparative analytical performance study for molecular detection of low amounts of Toxoplasma gondii from simulated specimens. J Clin Microbiol. 2010;48(9):3216–22.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Roux G, Varlet-Marie E, Bastien P, Sterkers Y. French National Reference Center for toxoplasmosis network. Evolution of Toxoplasma-PCR methods and practices: a French national survey and proposal for technical guidelines. Int J Parasitol. 2018;48(9–10):701–7.

    Article  CAS  PubMed  Google Scholar 

  38. Homan WL, Vercammen M, De Braekeleer J, Verschueren H. Identification of a 200- to 300-fold repetitive 529 bp DNA fragment in Toxoplasma gondii, and its use for diagnostic and quantitative PCR. Int J Parasitol. 2000;30(1):69–75.

    Google Scholar 

  39. Belaz S, Gangneux J-P, Dupretz P, Guiguen C, Robert-Gangneux F. A 10-year retrospective comparison of two target sequences, REP-529 and B1, for Toxoplasma gondii detection by quantitative PCR. J Clin Microbiol. 2015;53(4):1294–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Edvinsson B, Lappalainen M, Evengård B. ESCMID study Group for Toxoplasmosis. Real-time PCR targeting a 529-bp repeat element for diagnosis of toxoplasmosis. Clin Microbiol Infect. 2006;12(2):131–6.

    Article  CAS  PubMed  Google Scholar 

  41. Robert-Gangneux F, Belaz S. Molecular diagnosis of toxoplasmosis in immunocompromised patients. Curr Opin Infect Dis. 2016;29(4):330–9.

    Article  PubMed  Google Scholar 

  42. Correia CC, Melo HRL, Costa VMA. Influence of neurotoxoplasmosis characteristics on real-time PCR sensitivity among AIDS patients in Brazil. Trans R Soc Trop Med Hyg. 2010;104(1):24–8.

    Article  PubMed  Google Scholar 

  43. Anselmo LMP, Vilar FC, Lima JE, Yamamoto AY, Bollela VR, Takayanagui OM. Usefulness and limitations of polymerase chain reaction in the etiologic diagnosis of neurotoxoplasmosis in immunocompromised patients. J Neurol Sci. 2014;346(1–2):231–4.

    Article  PubMed  Google Scholar 

  44. Petersen E, Edvinsson B, Lundgren B, Benfield T, Evengård B. Diagnosis of pulmonary infection with Toxoplasma gondii in immunocompromised HIV-positive patients by real-time PCR. Eur J Clin Microbiol Infect Dis. 2006;25(6):401.

    Article  CAS  PubMed  Google Scholar 

  45. Bourdin C, Busse A, Kouamou E, Touafek F, Bodaghi B, Le Hoang P, et al. PCR-based detection of Toxoplasma gondii DNA in blood and ocular samples for diagnosis of ocular toxoplasmosis. J Clin Microbiol. 2014;52(11):3987–91.

    Google Scholar 

  46. De Groot-Mijnes JDF, Rothova A, Van Loon AM, Schuller M, Ten Dam-Van Loon NH, De Boer JH, et al. Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthalmol. 2006;141(2):313–8.

    Google Scholar 

  47. Errera M-H, Goldschmidt P, Batellier L, Degorge S, Héron E, Laroche L, et al. Real-time polymerase chain reaction and intraocular antibody production for the diagnosis of viral versus toxoplasmic infectious posterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(12):1837–46.

    Article  PubMed  Google Scholar 

  48. Scheepers MA, Lecuona KA, Rogers G, Bunce C, Corcoran C, Michaelides M. The value of routine polymerase chain reaction analysis of intraocular fluid specimens in the diagnosis of infectious posterior uveitis. ScientificWorldJournal. 2013;2013:545149.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Fardeau C, Romand S, Rao NA, Cassoux N, Bettembourg O, Thulliez P, et al. Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am J Ophthalmol. 2002;134(2):196–203.

    Article  PubMed  Google Scholar 

  50. Talabani H, Asseraf M, Yera H, Delair E, Ancelle T, Thulliez P, et al. Contributions of immunoblotting, real-time PCR, and the Goldmann-Witmer coefficient to diagnosis of atypical toxoplasmic retinochoroiditis. J Clin Microbiol. 2009;47(7):2131–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Patrat-Delon S, Gangneux J-P, Lavoué S, Lelong B, Guiguen C, Le Tulzo Y, et al. Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis. J Clin Microbiol. 2010;48(7):2541–5.

    Google Scholar 

  52. Menotti J, Vilela G, Romand S, Garin YJ-F, Ades L, Gluckman E, et al. Comparison of PCR-enzyme-linked immunosorbent assay and real-time PCR assay for diagnosis of an unusual case of cerebral toxoplasmosis in a stem cell transplant recipient. J Clin Microbiol. 2003;41(11): 5313–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Rodríguez Carnero P, Hernández Mateo P, Martín-Garre S, García Pérez Á, del Campo L. Unexpected hosts: imaging parasitic diseases. Insights Imaging. 2017;8(1):101–25.

    Google Scholar 

  54. Sakamoto N, Maeda T, Mikita K, Kato Y, Yanagisawa N, Suganuma A, et al. Clinical presentation and diagnosis of toxoplasmic encephalitis in Japan. Parasitol Int. 2014;63(5): 701–4.

    Article  PubMed  Google Scholar 

  55. Weenink JJ, Weenink AG, Geerlings SE, van Gool T, Bemelman FJ. Severe cerebral toxoplasma infection cannot be excluded by a normal CT scan. Neth J Med. 2009;67(4):3.

    Google Scholar 

  56. Mueller-Mang C, Mang TG, Kalhs P, Thurnher MM. Imaging characteristics of toxoplasmosis encephalitis after bone marrow transplantation: report of two cases and review of the literature. Neuroradiology. 2006;48(2):84–9.

    Article  CAS  PubMed  Google Scholar 

  57. Sumi M, Norose K, Hikosaka K, Kaiume H, Takeda W, Kirihara T, et al. Clinical characteristics and computed tomography findings of pulmonary toxoplasmosis after hematopoietic stem cell transplantation. Int J Hematol. 2016;104(6):729–40.

    Article  PubMed  Google Scholar 

  58. Lavinsky D, Romano A, Muccioli C, Belfort R. Imaging in ocular toxoplasmosis. Int Ophthalmol Clin. 2012;52(4):131–43.

    Article  PubMed  Google Scholar 

  59. Martino R, Maertens J, Bretagne S, Rovira M, Deconinck E, Ullmann AJ, et al. Toxoplasmosis after hematopoietic stem cell transplantation. Clin Infect Dis. 2000;31(5):1188–95.

    Article  CAS  PubMed  Google Scholar 

  60. Campbell AL, Goldberg CL, Magid MS, Gondolesi G, Rumbo C, Herold BC. First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation. Transplantation. 2006;81(3): 408–17.

    Article  PubMed  Google Scholar 

  61. Konstantinovic N, Guegan H, Stäjner T, Belaz S, Robert-Gangneux F. Treatment of toxoplasmosis: current options and future perspectives. Food Waterborne Parasitol. 2019;15:e00036.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4):e00057-17.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207; quiz CE1-4.

    PubMed  Google Scholar 

  64. European AIDS Clinical Society (EACS). EACS guidelines 2018 [Internet]. http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf

  65. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992;116(1):33–43.

    Article  CAS  PubMed  Google Scholar 

  66. Katlama C, De Wit S, O’Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996;22(2):268–75.

    Google Scholar 

  67. Torre D, Casari S, Speranza F, Donisi A, Gregis G, Poggio A, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998;42(6):1346–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant. 2002;29(8):691–8.

    Article  CAS  PubMed  Google Scholar 

  69. Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis. 2002;34(9):1243–50.

    Article  CAS  PubMed  Google Scholar 

  70. Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, Leport C, et al. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1993;12(11):853–6.

    Article  CAS  PubMed  Google Scholar 

  71. Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS. 2001;15(5):583–9.

    Article  CAS  PubMed  Google Scholar 

  72. Gallant J. Get rich quick with old generic drugs! The Pyrimethamine pricing scandal. Open Forum Infect Dis. 2015;2(4):1–2.

    Article  Google Scholar 

  73. Goswami RP, Goswami RP, Rahman M, Ray Y, Tripathi SK. Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting. Int J STD AIDS. 2015;26(12):864–9.

    Article  CAS  PubMed  Google Scholar 

  74. Arens J, Barnes K, Crowley N, Maartens G. Treating AIDS-associated cerebral toxoplasmosis – pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids. S Afr Med J. 2007;97(10):956–8.

    PubMed  Google Scholar 

  75. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):102–14.

    Article  PubMed  Google Scholar 

  76. Jasper S, Vedula SS, John SS, Horo S, Sepah YJ, Nguyen QD. Corticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database Syst Rev. 2017;2017(1):CD007417.

    PubMed Central  Google Scholar 

  77. Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013;41(1):95–108.

    Article  PubMed  Google Scholar 

  78. Ozgonul C, Besirli CG. Recent developments in the diagnosis and treatment of ocular toxoplasmosis. Ophthalmic Res. 2017;57(1):1–12.

    Article  PubMed  CAS  Google Scholar 

  79. Rothova A, Meenken C, Buitenhuis HJ, Brinkman CJ, Baarsma GS, Boen-Tan TN, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115(4):517–23.

    Article  CAS  PubMed  Google Scholar 

  80. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MSA, van Ruyven RLJ, Klok AM, Hoyng CB, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):34–40.

    Google Scholar 

  81. Chung H, Kim J-G, Choi S-H, Lee SY, Yoon YH. Bilateral Toxoplasma Retinochoroiditis simulating Cytomegalovirus retinitis in an allogeneic bone marrow transplant patient. Korean J Ophthalmol. 2008;22(3):197–200.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Mouri O, Kendjo E, Touafek F, Fekkar A, Konte O, Imbert S, et al. The impact of lowering the cut-off value on the sensitivity of the Platelia Elisa IgG (Bio-Rad) test for toxoplasmosis diagnosis. Parasite. 2015;22:22.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Olariu TR, Press C, Talucod J, Olson K, Montoya JG. Congenital toxoplasmosis in the United States: clinical and serologic findings in infants born to mothers treated during pregnancy. Parasite. 2019;26:13.

    Article  PubMed  PubMed Central  Google Scholar 

  84. La Hoz RM, Morris MI, Infectious Diseases Community of Practice of the American Society of Transplantation. Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13546.

    Google Scholar 

  85. Chehrazi-Raffle A, Luu M, Yu Z, Liou F, Kittleson M, Hamilton M, et al. Toxoplasma gondii serology and outcomes after heart transplantation: contention in the literature. Transplant Proc. 2015;47(6):1949–53.

    Article  CAS  PubMed  Google Scholar 

  86. van Hellemond JJ, van Domburg RT, Caliskan K, Birim O, Balk AH. Toxoplasma gondii serostatus is not associated with impaired long-term survival after heart transplantation. Transplantation. 2013;96(12):1052–8.

    Google Scholar 

  87. Sarchi E, Genco F, Di Matteo A, Castiglioni B, Minoli L, Meroni V. Surveillance of Toxoplasma gondii infection in recipients of thoracic solid organ transplants. New Microbiol. 2007;30(3):299–302.

    Google Scholar 

  88. Miltgen G, Paillot J, Vanlemmens C, Di Martino V, Heyd B, Millon L, et al. Fatal acute respiratory distress by Toxoplasma gondii in a toxoplasma seronegative liver transplant recipient. New Microbiol. 2016;39(2):160–2.

    Google Scholar 

  89. Vaessen N, Verweij JJ, Spijkerman IJB, van Hoek B, van Lieshout L. Fatal disseminated toxoplasmosis after liver transplantation: improved and early diagnosis by PCR. Neth J Med. 2007;65(6):222–3.

    Google Scholar 

  90. Rogers NM, Peh C-A, Faull R, Pannell M, Cooper J, Russ GR. Transmission of toxoplasmosis in two renal allograft recipients receiving an organ from the same donor. Transpl Infect Dis. 2008;10(1):71–4.

    Article  CAS  PubMed  Google Scholar 

  91. Martina M-N, Cervera C, Esforzado N, Linares L, Torregrosa V, Sanclemente G, et al. Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review. Transpl Int. 2011;24(1):e6–12.

    Article  PubMed  Google Scholar 

  92. Gourishankar S, Doucette K, Fenton J, Purych D, Kowalewska-Grochowska K, Preiksaitis J. The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation. 2008;85(7):980–5.

    Article  PubMed  Google Scholar 

  93. Wendum D, Carbonell N, Svrcek M, Chazouilléres O, Fléjou J-F. Fatal disseminated toxoplasmosis in a toxoplasma seropositive liver transplant recipient. J Clin Pathol. 2002;55(8): 637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Barcán LA, Dallurzo ML, Clara LO, Valledor A, Macías S, Zorkin E, et al. Toxoplasma gondii pneumonia in liver transplantation: survival after a severe case of reactivation. Transpl Infect Dis. 2002;4(2):93–6.

    Article  PubMed  Google Scholar 

  95. Botterel F, Ichai P, Feray C, Bouree P, Saliba F, Raspa RT, et al. Disseminated toxoplasmosis, resulting from infection of allograft, after Orthotopic liver transplantation: usefulness of quantitative PCR. J Clin Microbiol. 2002;40(5):1648–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Manz T, Grotz W, Orszagh M, Volk B, Kirste G, Neumann HP. A patient with neurological deficits and seizures after renal transplantation. Nephrol Dial Transplant. 2001;16(3):631–3.

    Article  CAS  PubMed  Google Scholar 

  97. Fontanet A, Chalandon Y, Roosnek E, Mohty B, Passweg JR. Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal. Bone Marrow Transplant. 2001;46(9): 1272–3.

    Article  CAS  Google Scholar 

  98. Baden LR, Katz JT, Franck L, Tsang S, Hall M, Rubin RH, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation. 2003;75(3):339–43.

    Article  CAS  PubMed  Google Scholar 

  99. Béraud G, Pierre-François S, Foltzer A, Abel S, Liautaud B, Smadja D, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994–2006. Am J Trop Med Hyg. 2009;80(4):583–7.

    Article  PubMed  Google Scholar 

  100. Podzamczer D, Miró JM, Ferrer E, Gatell JM, Ramón JM, Ribera E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. Eur J Clin Microbiol Infect Dis. 2000;19(2):89–95.

    Article  CAS  PubMed  Google Scholar 

  101. Robert-Gangneux F. It is not only the cat that did it: how to prevent and treat congenital toxoplasmosis. J Infect. 2014;68:S125–33.

    Article  PubMed  Google Scholar 

  102. Carme B, Bissuel F, Ajzenberg D, Bouyne R, Aznar C, Demar M, et al. Severe acquired toxoplasmosis in Immunocompetent Adult Patients in French Guiana. J Clin Microbiol. 2002;40(11):4037–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Pena HFJ, Gennari SM, Dubey JP, Su C. Population structure and mouse-virulence of Toxoplasma gondii in Brazil. Int J Parasitol. 2008;38(5):561–9.

    Article  CAS  PubMed  Google Scholar 

  104. Bretagne S, Costa J-M, Foulet F, Jabot-Lestang L, Baud-Camus F, Cordonnier C. Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients. Transpl Infect Dis. 2000;2(3):127–32.

    Article  CAS  PubMed  Google Scholar 

  105. Cavattoni I, Ayuk F, Zander AR, Zabelina T, Bacher A, Cayroglu E, et al. Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny. Leuk Lymphoma. 2010;51(8):1530–5.

    Article  CAS  PubMed  Google Scholar 

  106. Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA, et al. Toxoplasmosis after allogeneic stem cell transplantation – a single Centre experience. Ann Hematol. 2012;91(7):1081–9.

    Article  PubMed  Google Scholar 

  107. CDC-Centers for Disease Control and Prevention. CDC – Toxoplasmosis – Prevention & Control [Internet]. 2018. Disponible sur: https://www.cdc.gov/parasites/toxoplasmosis/prevent.html

Download references

Author information

Authors and Affiliations

  1. Univ Rennes, CHU Rennes, Inserm, EHESP, Irset UMR_S 1085, Rennes, France

    Hélène Guegan & Florence Robert-Gangneux

  2. Centre Hospitalier Universitaire de Rennes, Rennes, France

    Hélène Guegan & Florence Robert-Gangneux

  3. Study Group for Clinical Parasitology (ESGCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Basel, Switzerland

    Florence Robert-Gangneux

Authors
  1. Hélène Guegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florence Robert-Gangneux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florence Robert-Gangneux .

Editor information

Editors and Affiliations

  1. Immunocompromised Host Service Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

  2. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Camille Nelson Kotton

  3. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

    Cameron R. Wolfe

Section Editor information

  1. Infectious Diseases Division, Harvard University Medical School, Boston, MA, USA

    Camille Nelson Kotton

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Guegan, H., Robert-Gangneux, F. (2021). Toxoplasma gondii in Solid Organ and Stem Cell Transplant: Prevention and Treatment. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25869-6_51

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25868-9

  • Online ISBN: 978-3-030-25869-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation